Precision therapy in congenital long QT syndrome

Raquel Neves, Sahej Bains, J. Martijn Bos, Ciorsti MacIntyre, John R. Giudicessi, Michael J. Ackerman

Research output: Contribution to journalReview articlepeer-review


Long QT syndrome (LQTS) is a potentially life-threatening, but highly treatable genetic heart disease. LQTS-directed therapies often consist of beta-blockers (BBs), left cardiac sympathetic denervation (LCSD), and/or an implantable cardioverter defibrillator (ICD). However, in clinical practice, many patient-specific and genotype-directed permutations exist. Herein, we aim to review the spectrum of treatment configurations utilized at a single, tertiary center specializing in the care of patients with LQTS to demonstrate optimal LQTS-directed management is not amenable to a “one-size-fits-all” approach but instead benefits from patient- and genotype-tailored strategies.

Original languageEnglish (US)
JournalTrends in cardiovascular medicine
StateAccepted/In press - 2022


  • Genetic testing
  • Long QT syndrome
  • Precision therapy
  • Sudden cardiac death

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Precision therapy in congenital long QT syndrome'. Together they form a unique fingerprint.

Cite this